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 Abstract 
  Aims:   To determine the effect of diabetes mellitus (DM) on regional cerebral blood flow (rCBF) 
patterns in patients with Alzheimer’s disease (AD).   Methods:   We investigated the initial rCBF of 
71 AD patients (36 without DM and 35 with DM) and the final rCBF of 23 AD patients (12 without 
DM and 11 with DM) after an average of 32 months. Single-photon emission computed tomog-
raphy (SPECT) data were analyzed by statistical brain imaging.  Results:  The initial SPECT showed 
that AD patients without DM had lower rCBF in the left and right inferior temporal gyri than AD 
patients with DM. A follow-up SPECT demonstrated that rCBF decreased in more widespread re-
gions, including the parietal, temporal, frontal, and limbic lobes, in AD patients without than with 
DM.  Conclusion:  This study suggests that functional brain abnormalities in AD differ depending 
on the DM status at baseline and during follow-up, reflecting neuropathologic differences. 
  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Epidemiologic studies have shown that diabetes mellitus (DM) is associated with an in-
creased risk of Alzheimer’s disease (AD)   [1]  . Although multiple possible mechanisms ex-
plaining the association between DM and AD have been proposed, it is known that insulin 
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resistance and peripheral hyperinsulinemia promote the neurodegeneration that occurs in 
AD, for example due to      amyloid (A    ) deposits and the increase of tau hyperphosphoryla-
tion   [2, 3]  . Indeed, some investigators have found that DM is associated with hippocampal 
and whole-brain atrophy   [4, 5]  . However, it remains unclear whether there are any patho-
physiologic differences between AD patients with and without DM. Moreover, it is contro-
versial whether DM also plays a role in the progression of the disease itself   [6–10]  .
    In the present study, we first examined the differences in regional cerebral blood flow 
(rCBF) deficits between AD patients with and without DM on initial single-photon emission 
computed tomography (SPECT) and then compared rCBF changes between initial and fol-
low-up SPECT in each group. Since rCBF deficits reflect functional brain abnormalities as-
sociated with neuronal degeneration, repeated rCBF measurement is considered to be an 
objective and reliable indicator of disease progression. To the best of our knowledge, this is 
the first study on the effect of DM on rCBF patterns in AD patients.
  Materials  and  Methods   
 Subjects 
  We retrospectively studied 71 AD outpatients with or without type 2 DM (27 men and 
44 women, mean age   8   SD 78.7   8   5.2 years) attending the Memory Clinic of our hospital. 
AD patients met the clinical criteria for probable AD established by the National Institute of 
Neurological and Communicative Disorders Association  [11]  and had mild-to-moderate AD 
defined according to a Clinical Dementia Rating score of 1 or 2   [12]  . All patients underwent 
detailed general physical, neurologic, and psychiatric examinations and extensive laboratory 
tests including brain computed tomography (CT) or magnetic resonance imaging (MRI) to 
exclude other potential causes of dementia. After the initial evaluation, including SPECT, 66 
of the 71 AD patients were given donepezil at a dose of 3 mg once daily for 2 weeks, followed 
by 5 mg daily thereafter, which was tolerated without serious adverse effects. They were fol-
lowed up for 24–48 months (mean follow-up time, 28.6   8   5.9 months), but we could only 
obtain both the initial and final SPECT data in 23 AD patients (12 without DM and 11 with 
DM) because the intervals between cognitive assessment and SPECT in AD patients with 
and without DM who were lost to follow-up were unfortunately more than 3 months. The 
severity of cognitive impairment was assessed using the Mini-Mental State Examination 
(MMSE)   [13]  . Progression of dementia was evaluated based on a comparison of the MMSE 
scores on the initial evaluation and the final evaluation. Subjects were excluded if they had 
extensive white matter lesions (e.g., low-density lesions on CT or high-intensity lesions on 
T2-weighted MRI grade 3) using the scale of Fazekas et al.   [14]   and territorial or cortical in-
farctions. DM was defined as the use of an oral hypoglycemic drug or a casual (non-fasting) 
plasma glucose level of   6  200 mg/dl according to a report by the Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus  [15] . The patients were divided into an AD 
without DM group (n = 36) and an AD with DM group (n = 35). The AD with DM group 
had been diagnosed with type 2 DM, and the duration of DM ranged from a few years to 
more than 30 years on the initial SPECT. Moreover, 10 of the 35 AD patients with DM had 
already been receiving medication with oral hypoglycemic agents, including sulfonylureas, 
biguanides, and     -glucosidase inhibitors at the time of initial SPECT, and 3 of the 11 AD 
patients with DM with final SPECT were additionally given thiazolidinediones after the ini-
tial SPECT. The interval between cognitive assessment and SPECT in all subjects was   ^ 3 
months.
    Twenty-eight control subjects (12 men and 16 women, age range 56–86 years, mean age 
  8   SD 77.1   8   6.4 years) who had no memory impairment, cognitive disorder, or abnormali-64
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ties on MRI were assigned to the normal control group. Written informed consent was ob-
tained from all subjects or their closest relative before the study. The study design was ap-
proved by the ethics review board of our hospital.
  MRI  Study 
  Brain MRI scans (axial T1- and T2-weighted images) at the initial evaluation were ob-
tained from 42 AD patients (22 with DM and 20 without DM) using a 1.5-tesla scanner 
(Magnetom; Siemens Medical Systems, Erlangen, Germany) with the following parameters: 
T1-weighted spin echo (TR 450 ms; TE 12 ms; FOV 250 mm, matrix 256   !   256) and T2-
weighted fast spin echo (TR 3,540 ms; TE 106 ms; FOV 250 mm, matrix 256   !   256). Quali-
tative MRI analysis was performed by blinded investigators who assessed periventricular and 
deep white matter hyperintensities (grades 0, 1, and 2 based on the scale of Fazekas et al.  [14] ), 
and lacunar infarctions (defined by low intensity on T1-weighted imaging and high inten-
sity on T2-weighted imaging with a diameter   !  15 mm) in the deep gray and white matter 
(infarctions were rated as follows: no, single, and multiple).
  SPECT  Study 
 All subjects underwent examination using a triple-head rotating gamma camera (SPECT 
Picker 3000 XP; Eclipse Systems, Durham, Conn., USA) with a fan beam, permitting a spa-
tial resolution of 6.8 mm full width at half maximum, approximately 15 min after an intra-
venous bolus injection of 222 MBq of N-isopropyl-p-[  123  I]-iodoamphetamine. Prior to the 
injection, the subjects were allowed to rest in a quiet, dimly lit environment for 10 min. 
SPECT acquisition was undertaken in 24 steps (72 projections), in each of which counts were 
collected for 40 s. Reconstruction of the images was performed by filters (order 8; cutoff 0.40/
cm) with attenuation correction (Chang method 0.09/cm). The matrix size and slice thick-
ness of SPECT images were 128   !   128 and 4.3 mm, respectively.
  Three-dimensional stereotactic surface projections created with the Neurological Statis-
tical Image Analysis software developed by Minoshima et al.   [16]   were employed to evaluate 
the spatial distribution of abnormal perfusion. Each image set was realigned to the bicom-
missure stereotactic coordinate system   [17]  . The differences in individual brain size were 
eliminated by linear scaling, and regional anatomical differences were minimized by a non-
linear warping technique. Each brain was therefore standardized anatomically to match a 
standard atlas brain while preserving regional perfusion activity. Subsequently, maximum 
cortical activity was extracted to adjacent predefined surface pixels on a pixel-by-pixel basis 
using three-dimensional stereotactic surface projections. Data sets were normalized to the 
mean global activity. To quantify rCBF deficits, the normalized brain activity of each patient 
was compared with that of 28 normal controls using pixel-by-pixel z-score analysis: (normal 
mean) – (individual value)/(normal SD). A positive z-score represented a reduced rCBF in 
the patient in comparison with the normal control mean.
    To demonstrate rCBF alterations, 2-sample t test values were calculated on a pixel-by-
pixel basis between controls and each group on the initial SPECT, and then converted to z-
values by a probability integral transformation. Furthermore, to assess rCBF changes, intra-
group differences between the initial and final SPECT data (after about 32 months) were 
compared: AD with DM group (n = 11) 32.3   8   6.0 months and AD without DM group
(n = 12) 31.5   8   6.5 months. Next, to measure rCBF reduction, the mean z-score for each pa-
tient was calculated by the stereotactic extraction estimation method   [18]  . Mean z-scores for 
each gyrus of the frontal, parietal, temporal, occipital, and limbic lobes of the right and left 
hemispheres were automatically measured (average z-value of the coordinates with a z-value 
that exceeded 0 – the threshold value). The mean value in each patient was compared with 
the corresponding mean values of the 28 control subjects on a region-by-region basis, and 65
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the reduction in rCBF was expressed as a z-score. The method of rCBF measurement was 
described in detail elsewhere   [19]  .
  Statistical  Analysis 
  Values were expressed as means   8   SD. Statistical analysis was performed using Stu-
dent’s t test,     2   test, Mann-Whitney U test, and Wilcoxon signed-rank test. A comparison of 
mean z-scores for cerebral subregions between the two groups was performed by one-way 
ANOVA and post hoc t tests with Bonferroni’s corrections. A p value   !  0.05 was considered 
to indicate a statistically significant difference.
  R e s u l t s  
  Patient characteristics of the two groups are summarized in   tables 1   and   2  . There were 
no significant differences between the AD without DM group and the AD with DM group 
with regard to age, gender, education, duration of symptoms, initial MMSE score, follow-up 
duration, use of an acetylcholinesterase inhibitor (donepezil), or blood pressure on medical 
examination. Moreover, age did not significantly differ between patients and controls. The 
average initial and final MMSE scores were 21.7  8  3.0 and 19.6  8  3.5 in the AD without DM 
group who were lost for the final SPECT, and 20.8  8   3.6 and 20.3   8   3.5 in the AD with DM 
group who were lost for the final SPECT, respectively. By definition, although fasting plasma 
glucose and hemoglobin A  1c   levels were normal in the AD without DM group, they were 
higher in the AD with DM group. MMSE scores at the final evaluation were significantly 
lower compared with the initial evaluation in the AD without DM group, but not in the AD 
Table 1.   Characteristics of the whole study group
AD without DM group
(n = 36)
AD with DM group
(n = 35)
Age, years 78.385.0 79.185.5
Gender, men/women 15/21 12/23
Education, years 12.282.9 12.383.0
Duration of AD, years 2.580.7 2.281.2
Initial MMSE score 21.783.1 21.283.8
Final MMSE score 18.784.0*, ** 21.184.5
Follow-up period, months 27.784.1 30.188.1
Fasting plasma glucose, mg/dl 97.586.9# 152.7838.6
Hemoglobin A1c, % 5.380.4## 7.181.6
Medication, n of patients
Donepezil 35 31
DM 0 10
Sulfonylureas 8
Biguanides 2
-Glucosidase inhibitors 2
Thiazolidinediones 0
Hypertension 7 10
Hyperlipidemia 5 5
Initial blood pressure, mm Hg 139815/7788 134812/7687
V  alues are expressed as means 8 SD or numbers of patients. * p < 0.05 vs. initial MMSE score.
** p < 0.05 vs. AD with DM group. # p < 0.05 vs. AD with DM group. ## p < 0.05 vs. AD with DM group.66
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with DM group. As illustrated by  table 2 , the final hemoglobin A  1c  levels were lower than the 
initial levels, but the difference was only significant in the AD without DM group. 
    In   table 3  , qualitative MRI parameters are compared. There were no significant differ-
ences between the 20 AD patients without DM and the 22 AD patients with DM in terms of 
periventricular (    2   = 1.43, d.f. = 2) and deep white matter hyperintensity lesions (    2   = 0.05, 
d.f. = 2) or lacunar infarctions (    2   = 3.35, d.f. = 2). Sixteen patients without DM and 13 pa-
tients with DM in whom only brain CT was performed had no abnormal high- or low-den-
sity lesions in their parenchyma.
   Figure 1 a and b presents the relative decrease in rCBF in the AD without DM group and 
in the AD with DM group compared with normal controls on the initial SPECT, respective-
ly. Both groups showed significant decreases in rCBF in the parietotemporal lobes, posterior 
Table 2.   Characteristics of the patients presenting at the final follow-up
AD without DM
group (n = 12)
AD with DM
group (n = 11)
Age, years 78.984.6 77.986.3
Gender, men/women 6/6 5/6
Education, years 12.383.3 11.882.9
Duration of AD, years 2.480.9 2.080.8
Initial MMSE score 22.582.8 22.383.8
Final MMSE score 17.484.6*, ** 21.785.1
Initial fasting plasma glucose, mg/dl 97.787.0# 138.0826.0
Final fasting plasma glucose, mg/dl 107822## 132823
Initial hemoglobin A1c, % 4.880.3### 7.081.8
Final hemoglobin A1c, % 6.580.9
Duration of DM
≤3 years 7
3–10 years 0
10–20 years 4
>20 years 0
Duration of anti-DM medication
≤3 years 6
3–10 years 1
>10 years 3
Type of DM medication during follow-up 5
Sulfonylureas 1
Biguanides 2
-Glucosidase inhibitors 1
Thiazolidinediones 3
Initial blood pressure score 136817/7688 136817/7687
Final blood pressure score 127811/7689 138816/7588
Medication, n of patients
Hypertension 2 5
Calcium channel blockers 2 4
Angiotensin-converting enzyme inhibitors 0 1
Angiotensin-2 receptor blockers 0 0
Hyperlipidemia 2 4
Statins 1 3
Values are expressed as means 8 SD or numbers of patients.
* p < 0.05 vs. initial MMSE score. ** p < 0.05 vs. AD with DM group. # p < 0.05 vs. AD with DM 
group. ## p < 0.05 vs. AD with DM group. ### p < 0.05 vs. AD with DM group. 67
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cingulate and cinguloparietal transitional areas, and frontal association cortices, and these 
decreases are considered characteristic features of AD.  Figure 1 c compares three-dimension-
al views of decreased rCBF between AD patients with and without DM. Statistical mapping 
demonstrated that regions with decreased rCBF included the left and right inferior temporal 
gyri in the AD without DM group compared with the AD with DM group. However, the AD 
with DM group had no significantly decreased rCBF areas compared with the AD without 
DM group.
      Figure 2  a and b presents rCBF changes between initial and final SPECT in both groups. 
In the AD without DM group rCBF was decreased in the temporoparietal and cingulate gyri 
of the right and left hemispheres. In contrast, in the AD with DM group rCBF was decreased 
in small and scattered regions of the right and left hemispheres, including the anterior cin-
gulate region. Both groups showed improvement in rCBF levels in some regions of the fron-
tal and medial occipital lobes, and in the cerebellum.
  Mean z-scores for the cerebral subregions on the initial and final SPECT were compared 
in the two groups ( table 4 ). On the initial SPECT, z-scores for the left inferior temporal gyrus 
were significantly higher in the AD without DM group than in the AD with DM group. In 
comparison with the initial SPECT, the final SPECT showed significantly higher z-scores in 
widespread regions, including the frontal, parietal, temporal, and limbic lobes of the AD 
without DM group, and in the right anterior cingulate region of the AD with DM group. 
Neither group had significantly lower z-scores in any regions on the final SPECT compared 
with the initial SPECT.
  Discussion 
  We found that the AD without DM group had greater rCBF deficits at the initial evalu-
ation in the left and right inferior temporal gyri than the AD with DM group, even though 
both had comparable MMSE scores and duration of symptoms. According to the study of 
Delacourte et al.   [20]  , neurofibrillary degeneration with paired helical filament tau was sys-
tematically present and patients at the first stage of AD had large amounts of paired helical 
filament tau in the temporal cortex. Considering such findings, the higher hypoperfusion in 
Table 3.   Qualitative MRI analysis results
AD without DM group 
(n = 20)
AD with DM group 
(n = 22)
White matter lesions
Periventricular hyperintensity lesions
01 1 1 6
16 4
23 2
Deep white matter hyperintensity lesions
01 3 1 5
15 5
22 2
Lacunar infarctions
No 12 14
Single 4 7
multiple 4 168
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  Fig. 1.   Statistical maps showing the relative decrease in rCBF in the AD without DM group and AD with 
DM group. 
  Fig. 2.  Statistical maps showing the relative changes on repeated SPECT in the AD without DM group and 
AD with DM group. The red scale indicates the relative rCBF increase, and the blue scale the relative rCBF 
decrease. 69
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AD without DM group A  D with DM group
baseline month 32 baseline month 32 
Frontal lobe
Superior frontal gyrus L 1.0380.37 1.1180.34 0.9380.41 1.0280.58
R 0.9380.40 0.9980.43 0.9380.47 1.0580.62
Middle frontal gyrus L 1.0680.34 1.2580.50 1.0180.44 1.0580.75
R 1.1080.47 1.1280.55 0.9680.41 0.9780.51
Inferior frontal gyrus L 1.0680.44 1.3280.78 1.1980.47 1.2680.80
R 0.8680.47 0.9180.38 0.7980.32 0.8780.32
Medial frontal gyrus L 1.0280.36 1.1880.36 0.9580.42 1.0980.54
R 0.9680.32 1.1980.53* 1.0380.47 1.1180.65
Orbital gyrus L 0.8381.02 1.4781.02 0.9480.81 1.0280.97
R 1.4581.27 1.2280.76 0.7080.68 0.9581.10
Rectal gyrus L 0.9880.73 1.2280.74 0.8980.35 0.8380.66
R 0.8080.45 1.2080.61 0.7380.42 0.7380.56
Paracentral lobule L 0.4080.48 0.7180.61* 0.5780.42 0.6180.31
R 0.4680.34 0.5180.43 0.4580.36 0.5980.21
Precentral gyrus L 0.8180.27 0.8980.35 0.7080.17 0.7680.32
R 0.7380.23 0.7880.29 0.6280.27 0.6780.27
Subcallosal gyrus L 0.9980.60 0.9980.41 0.7780.48 0.6980.38
R 0.5280.31 0.6880.42 0.6180.59 0.6880.34
Parietal lobe
Superior parietal lobule L 1.1280.49 1.3480.75 1.0580.22 1.0280.27
R 0.8980.50 1.0780.63 0.9380.12 1.0180.75
Inferior parietal lobule L 1.3580.76 1.7280.90* 1.3380.83 1.3280.84
R 1.0280.59  1.4380.96* 1.0880.70 1.2980.86
Angular gyrus L 1.2080.56 1.7681.09* 1.3580.76 1.3380.97
0.7480.88 1.4481.24* 1.2281.06 1.3881.19
Postcentral gyrus L 0.9580.51 0.8880.48 0.7680.37 0.7980.31
R 0.8380.33 0.7880.59 0.7280.27 0.8380.37
Precuneus L 0.8380.40 1.1580.67 1.1580.66 1.1480.55
R 0.7080.51 0.9580.69 0.9580.47 1.1280.54
Supramarginal gyrus L 1.3680.78 1.9081.15 1.5880.94 1.4481.21
R 0.8980.68 1.2981.12* 1.3780.92 1.2881.14
Temporal lobe
Superior temporal gyrus L 1.0880.38 1.3480.54 0.9180.17 1.0480.52
R 0.9180.52 1.3380.70* 0.8080.38 0.9580.38
Middle temporal gyrus L 1.1380.39 1.4780.73* 1.0080.41 1.1680.52
R 0.9280.78 1.2480.98* 0.8680.22 0.9580.35
Inferior temporal gyrus L 1.3780.81# 1.4581.05 0.9580.26 1.2180.51
R 1.1280.73 1.2580.80 0.9180.29 1.1380.49
Transverse temporal gyrus L 0.3980.59 0.5480.73 0.4980.45 0.5680.66
R 0.3980.45 0.4080.48 0.2980.47 0.4080.55
Occipital lobe
Superior occipital gyrus L 1.0580.96 1.1780.97 0.8080.46 0.6080.40
R 0.9180.96 1.0681.08 0.8580.81 0.8281.02
Middle occipital gyrus L 1.1780.87 1.4981.15 0.8180.33 0.9380.47
R 1.0880.84 1.2581.10 0.6680.46 0.9180.74
Inferior occipital gyrus L 0.6080.50 0.8480.68 0.5180.46 0.5080.45
R 0.8580.68 0.8380.92 0.6580.53 0.7080.75
Cuneus L 0.8980.63 0.7680.48 0.7580.34 0.7680.43
R 0.7280.60 0.7080.42 0.6880.37 0.6580.60
Fusiform gyrus L 1.5380.84 1.4680.98 0.8080.38 1.1980.56
R 1.0780.62 1.2880.74 0.7180.26 1.0180.48
Lingual gyrus L 0.6280.75 0.3880.32 0.5480.43 0.6780.50
R 0.5880.55 0.4480.59 0.5080.70 0.4280.45
Table 4.   Results of z-scores for each cerebral subregion on initial and final SPECT70
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the left and right inferior temporal gyri may reflect more severe neuronal degeneration by 
AD pathology. Moreover, compared with the initial SPECT, in the follow-up SPECT, rCBF 
in the AD without DM group was significantly reduced in widespread regions, including the 
parietal, temporal, frontal, and limbic lobes, whereas it was significantly reduced only in the 
anterior cingulate region in the AD with DM group. Our results suggest that functional brain 
abnormalities of AD differ depending on DM status at baseline and during follow-up.
  Some investigators have examined the relation of DM with the neuropathologic features 
of AD, including neuritic plaques and neurofibrillary tangles, but the results were inconclu-
sive   [21–25]  . One study only found an association (with the     4 allele) in a subgroup of indi-
viduals with DM   [21]  , whereas others failed to demonstrate an association between DM and 
the histopathologic features of AD   [22–24]  . Beeri et al.   [25]   found that DM was associated 
with less AD neuropathology. However, Launer   [26]   reported that, compared with non-DM 
individuals, those with DM have structural brain changes that reflect neuronal degeneration 
as well as vascular damage, and it is likely that DM leads to microstructural changes not ob-
served on MRI. Therefore, we assume that microvascular abnormalities may more strongly 
affect the pattern of rCBF deficits in the AD with DM group than in the AD without DM 
group, although our MRI study demonstrated that the involvement of the damaged white 
matter and the number of lacunar infarctions were not significantly different in the two 
groups. In a recent study, Sonnen et al.   [27]   observed two patterns of cerebral damage in pa-
tients with dementia according to DM status. In non-DM individuals, dementia was associ-
ated with a greater A     burden, whereas in DM individuals, dementia was associated with 
more microvascular infarctions. A recent clinical cohort study revealed that cognitive de-
cline during follow-up was faster in AD alone than in AD combined with cerebrovascular 
disease   [28]  . In the present study, the AD with DM group had less rCBF deficits in the infe-
rior temporal gyrus on the initial SPECT and we consider that they had slower cognitive de-
cline than the AD without DM group during the follow-up time, even though the MMSE 
scores and duration of disease were comparable on the initial SPECT, because they may have 
had brain damage, including microvascular or metabolic abnormalities intrinsic to DM, but 
with less AD neuropathology than the AD without DM group.
AD without DM group A  D with DM group
baseline month 32 baseline month 32 
Limbic lobe
Thalamus L 0.2580.27 0.2480.38 0.2680.18 0.3280.30
R 0.2580.31 0.2980.34 0.2880.26 0.3780.54
Cingulate gyrus L 0.8480.35 1.1680.23* 0.8580.33 1.0680.26
R 0.8380.31 1.0080.23* 0.8080.36 1.0180.24
Parahippocampal gyrus L 1.2280.42 1.1480.64 0.7780.54 0.9280.50
R 0.6680.31 0.9180.44 0.7180.36 0.8180.54
Anterior cingulate gyrus L 0.9680.43 1.2780.58* 0.9680.31 1.2280.62
R 0.8380.42 1.1380.49 0.8780.34 1.1680.46*
Posterior cingulate gyrus L 0.8480.50 1.1280.42 1.0080.54 1.0780.57
R 0.6980.52 0.8780.37 0.7480.47 0.9580.56
Uncus L 1.5080.67 1.5481.06 0.8680.47 1.0880.66
R 0.9880.42 0.8280.49 0.8280.39 1.0380.60
* p < 0.05 vs. baseline score. # p < 0.05 vs. AD with DM at baseline.
Table 4   (continued)71
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    Several studies have examined the effect of DM on the rate of cognitive decline   [6–10]  . 
However, the results are controversial; some found faster  [6]  or slower  [7, 8]  cognitive decline 
in AD patients with DM, or even no effects of DM on the rate of cognitive decline   [9, 10]  . 
Although the Rotterdam study reported the effects of antidiabetic medication on the patho-
genesis of clinical AD   [29]  , the Sacramento Area Latino Study on Aging (SALSA) illustrated 
that antidiabetic drugs appear to be useful for alleviating cognitive decline among individu-
als with DM, especially for those with a longer duration of disease   [30]  . A recent study in a 
large autopsy cohort demonstrated that the combination of insulin with other DM medica-
tion is associated with less AD neuropathology   [31]  . In this study, about 36% of the subjects 
had DM for   1  10 years, and in about 64% of the subjects DM was diagnosed within the last 3 
years. Because   1  60% of patients were relatively newly diagnosed, we cannot discount the 
possibility that the AD with DM group in our study is not representative of the entire DM 
population and thus carries a survival advantage which may be associated with a less aggres-
sive cognitive decline. Insulin-sensitizing agents, such as rosiglitazone and pioglitazone (ag-
onists of PPAR    ), have been shown to inhibit inflammatory gene expression, alter A     ho-
meostasis, and exhibit neuroprotective effects. Recent clinical trials have found that agonists 
of PPAR     improve cognition and memory in AD patients   [32]  . In the present study, PPAR    
agonists might have affected rCBF changes because 3 of the 11 AD patients with DM during 
the follow-up period were given thiazolidinediones after the initial SPECT. In addition, an-
tihypertensive drugs and statins, which were more frequently administered in DM patients 
than in non-DM subjects, may offer some therapeutic relief for AD patients. Recent studies 
have found evidence that some antihypertensive medications, including calcium channel 
blockers   [33]  , angiotensin-converting enzyme inhibitors   [34]  , angiotensin-2 receptor block-
ers   [35]   and statins   [36]  , prevent the incidence of AD, reduce cognitive decline, and are as-
sociated with less severe AD pathology. These findings explain the slower rate of cognitive 
and functional decline in patients with DM. However, it is unlikely that antihypertensive 
medications and statins had any effects in the present study, because the blood pressure data 
in both groups were good at the initial and final evaluation, and hypertensive medication did 
not significantly differ between the initial and final evaluation.
    Our study has some limitations. First, follow-up SPECT was only obtained in one third 
of the patients (12 patients without DM and 11 patients with DM), which raises the possibil-
ity that patients with dramatic deterioration of dementia were lost to follow-up SPECT. How-
ever, patients included in the follow-up SPECT are possibly representative of the entire pop-
ulation, since their clinical and demographic characteristics were comparable to those of the 
entire cohort. Despite the relatively small study cohort, there were clear differences in rCBF 
decline between patients with and without DM. Second, this study lacked non-demented DM 
subjects as a control group. We believe that the comparison of rCBF in the AD with DM 
group with the non-demented DM subjects was necessary in order to closely investigate 
rCBF patterns in the AD with DM group, because rCBF patterns may differ between non-
demented DM patients and normal controls. Third, although our AD diagnosis was not neu-
ropathologically confirmed, neuroimaging studies were used as part of the diagnostic pro-
cess. In particular, rCBF reductions in the parietotemporal association cortex on SPECT are 
recognized as a diagnostic pattern for AD, and SPECT provides a higher specificity for oth-
er types of dementia than clinical criteria   [37]  . As our patients presented characteristic fea-
tures of rCBF patterns in AD on baseline SPECT, we feel confident that all cases in the pres-
ent series of AD did indeed have AD. Fourth, it remains uncertain whether MMSE is the 
more appropriate instrument for assessing cognitive decline in AD. Although disease sever-
ity was measured using MMSE in this study, a single measurement may be an imperfect in-
dex of the rate of change in symptoms over an extended period. Be that as it may, a recent 
study revealed that the validity of measurements of the rate of change in MMSE was reliable 72
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when observations were separated by 3 years or more  [38] . As we followed up our patients for 
24–48 months, the rate of cognitive decline is likely to be a reliable parameter for assessing 
the cognitive decline in AD. Fifth, although the present analysis assumes a constant rate of 
decline, the rate of decline in neuropsychologic function can be quite variable. MMSE scores 
may plateau, especially in the very early stages of AD. Since our patients had mild-to-mod-
erate stages defined by a mean MMSE score of approximately 21 at the initial evaluation, 
most patients may have a relatively steady course of cognitive decline. Furthermore, almost 
all patients in this study were treated with donepezil, which may slow the clinical progres-
sion of AD. Therefore, the rate of cognitive decline in our patients may be different from that 
in patients who never used cholinesterase inhibitors. Thus, the effect of medication on clin-
ical progression should be taken into consideration, since the majority of patients examined 
in this study have been treated with a cholinesterase inhibitor.
  Conclusion 
  In the initial SPECT, a lower rCBF in the left and right inferior temporal gyri was ob-
served in the AD without DM group than in the AD with DM group. A follow-up SPECT 
showed that, in the AD without DM group, rCBF decreased in more widespread regions, in-
cluding the parietal, temporal, frontal, and limbic lobes, than in the AD with DM group. 
Functional brain abnormalities in AD may differ depending on the DM status at baseline 
and during follow-up, reflecting neuropathologic differences. 
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